Search

Displaying results 5421 - 5430 of 10000 in total
  1. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.

  2. Drug

    Cyclopenthiazide

    go.drugbank.com/drugs/DB13532
    Approved

    In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients [A27180]. … It is a positive allosteric modulator at AMPA-A receptors [T28].

  3. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase

  4. Drug

    Abexinostat

    go.drugbank.com/drugs/DB12565
    Investigational

    It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. … Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others.

  5. Drug

    Hydracarbazine

    go.drugbank.com/drugs/DB09243
    Experimental

    Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

  6. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. … NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer).

  7. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. … The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_.

  8. Drug

    Galidesivir

    go.drugbank.com/drugs/DB11676
    Investigational

    [L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19. … [A191451] In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.

    Synonyms: Immucillin A, Immucillin-A
  9. Drug

    BACTEK-R

    go.drugbank.com/drugs/DB16526
    Investigational

    Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood. … MV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections.

  10. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.